Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

M3, Inc. (MTHRY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
15.05+0.85 (+6.02%)
At close: 03:47PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.19
Open14.88
BidN/A x N/A
AskN/A x N/A
Day's Range14.54 - 15.05
52 Week Range12.62 - 41.49
Volume55,561
Avg. Volume69,360
Market Cap20.961B
Beta (5Y Monthly)0.91
PE Ratio (TTM)44.26
EPS (TTM)0.34
Earnings DateN/A
Forward Dividend & Yield0.06 (0.41%)
Ex-Dividend DateMar 29, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MTHRY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • M3 INC UNSPN ADS EACH REP 0.5 O
    CHDN: Raising target price to $200.00CHURCHILL DOWNS INC has an Investment Rating of HOLD; a target price of $200.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • PR Newswire

    M3-WAKE RESEARCH ACQUIRES MULTI-SPECIALTY RESEARCH ASSOCIATES OF LAKE CITY, FLORIDA

    M3 Wake Research, one of North America's largest leading fully integrated network of clinical research sites, announces the acquisition of Multi-specialty Research Associates (MSRA) in Lake City, Florida. This acquisition expands Wake Research's coast-to-coast coverage of clinical research populations in the United States and encompasses communities at 23 locations across eight states.

Advertisement
Advertisement